Nanoparticle-based next-generation influenza vaccines

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Head, Molecular Immunoengineering Unit, Viral Pathogenesis Laboratory, Vaccine Research Center, NIAID
    Biography

      Dr. Kanekiyo serves as Scientific Lead of the Influenza Program at the Vaccine Research Center (VRC), NIAID, NIH. In this role, he leads scientific research on basic, preclinical, and translational aspects of candidate influenza vaccines developed in the VRC. In addition, he is Head of Molecular Immunoengineering Unit, in which his team tackles complex immunology and vaccinology questions utilizing techniques in immunoengineering, protein engineering, molecular virology, synthetic biology, structural biology, and biochemistry. Dr. Kanekiyo is an immunologist, and a virologist who studies vaccine technologies, viral immunity, and host pathogen interaction. His work is centered on influenza virus, herpesvirus, and (re)emerging viruses. Dr. Kanekiyo obtained his D.V.M. from the Nihon University, Japan in 2002, and earned his Ph.D. in Veterinary Medicine with concentration on Molecular and Microbiology at the Nihon University Graduate School of Veterinary Medicine in 2006. Prior to the current appointment he was a postdoctoral fellow in the laboratory of Dr. Gary Nabel at the VRC focusing on HIV and influenza immunogen design. Dr. Kanekiyo is an inventor of several vaccine related technologies including the self-assembling nanoparticle-based influenza vaccines, that are currently evaluated in human phase I clinical trials.


    Abstract

    Most currently used conventional influenza vaccines are based on 1940s technology. Advances in immunogen design and vaccine delivery emerging over the last decade open novel opportunities for improving influenza vaccines that are previously inaccessible. These next-generation vaccine design tools are particularly promising in their potential to provide solutions to challenging targets for which conventional approaches have proven ineffective—for example, a universal influenza vaccine. Among the new vaccine technologies, nanoparticle-based vaccines have unique properties that are highly designable and programable. I will discuss our efforts on the development of next-generation nanoparticle-based influenza vaccines to elicit broad and potent protective immunity to influenza virus. A few of such designed nanoparticle-based influenza vaccine candidates are currently evaluated in human clinical trials.

    Learning Objectives:

    1. Nanoparticle-based immunogen design to elicit broad and potent protective immunity to influenza virus

    2. How immunofocusing to the viral sites of vulnerability can be achieved through immunogen design


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    JUL 22, 2020 10:00 AM PDT
    C.E. CREDITS
    JUL 22, 2020 10:00 AM PDT
    DATE: July 23, 2020 TIME: 10:00 am PDT The SARS-CoV-2 pandemic has taken a toll on many sectors of the medical community. As the pandemic took a grip on the laboratory, the need for diagnost...
    JUN 09, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    Loading Comments...
    Show Resources